Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02862912 · ClinicalTrials.gov registry record · Phase 4
Chloroprocaine Spinal Anesthesia for Cervical Cerclage (CP Spinal)
A Phase 4 study of Adverse Reaction to Spinal Anesthetic and Maternal Care for Cervical Incompetence, sponsored by Columbia University.
- Completed
- Registry status
- Phase 4
- Development phase
- 43
- Enrollment target
- 1
- Study location
NCT02862912: Completed Phase 4 study of Adverse Reaction to Spinal Anesthetic and Maternal Care for Cervical Incompetence, sponsored by Columbia University.
NCT02862912 is a Phase 4 study of Adverse Reaction to Spinal Anesthetic and Maternal Care for Cervical Incompetence that has completed, run by Columbia University. The registered enrollment target is 43 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02862912, a Phase 4 study of Adverse Reaction to Spinal Anesthetic and Maternal Care for Cervical Incompetence, has completed, sponsored by Columbia University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 43 participants
- Enrollment target
- 1
- Study location
Study Summary
This study aims to determine whether or not spinal anesthesia with the local anesthetic drug, chloroprocaine, wears off faster than the local anesthetic drug, bupivacaine, and results in faster discharge from the post-anesthesia care unit after surgery.
Primary Outcome
The mean difference between groups in time between the end of spinal injection (t IT) to time for no motor block (t motor), i.e. tIT - T motor. Motor block will be assessed using the Bromage scale: Bromage Scale I = free movement of the legs and feet = no block II = able to flex knees, with free movement of feet = partial (33%) block III = unable to flex knees, but with free movement of the feet = almost complete (66%) block IV = unable to move legs or feet = complete block (100%)
Conditions Studied
Interventions
- DRUG Bupivacaine
- DRUG Saline
- DRUG Fentanyl
- DRUG Chloroprocaine
Study Locations (1)
New York
- New York Presbyterian Hospital - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2016-11-08 |
| Est. Completion | 2020-01-31 |
| Phase | Phase 4 |
What the finished NCT02862912 record still lists
NCT02862912 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 43 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (92% lower).
The record links to 2 conditions, with Adverse Reaction to Spinal Anesthetic appearing as the primary indexed condition, and to 4 interventions - of which Bupivacaine is the first listed.
NCT02862912 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT02862912 about?
NCT02862912 is a clinical study titled "Chloroprocaine Spinal Anesthesia for Cervical Cerclage (CP Spinal)". This study aims to determine whether or not spinal anesthesia with the local anesthetic drug, chloroprocaine, wears off faster than the local anesthetic drug, bupivacaine, and results in faster discharge from the post-anesthesia care unit after surgery.
What is the current status of trial NCT02862912?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 43 participants. The study started on 2016-11-08. Estimated completion is 2020-01-31.
What conditions does trial NCT02862912 study?
This clinical trial studies the following conditions: Adverse Reaction to Spinal Anesthetic, Maternal Care for Cervical Incompetence.
What interventions are being tested in trial NCT02862912?
The interventions under investigation include: Bupivacaine (DRUG), Saline (DRUG), Fentanyl (DRUG), Chloroprocaine (DRUG).
Who is sponsoring clinical trial NCT02862912?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02862912 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02862912's enrollment target sits among peer trials
43 1371st of 2000 higher than 622 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03726359 · 43 participants · Phase 1
Phase I Study of Fractionated Stereotactic Radiation Therapy
- NCT03850418 · 43 participants · Phase 2
Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant
- NCT04144023 · 43 participants · Phase 1
A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ
- NCT04176718 · 43 participants · Phase 2
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI